Edesa Biotech, Inc. (EDSA)
NASDAQ: EDSA · Real-Time Price · USD
4.760
-0.020 (-0.42%)
At close: Sep 2, 2026, 4:00 PM EDT
4.970
+0.210 (4.41%)
After-hours: Sep 2, 2026, 7:48 PM EDT
Edesa Biotech Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
17
Market Cap
64.31M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Sep 30, 2025 | - | - | - |
| Sep 30, 2024 | - | - | - |
| Sep 30, 2023 | - | - | - |
| Sep 30, 2022 | - | - | - |
| Sep 30, 2021 | - | - | - |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| BioStem Technologies | 34.59M |
| MindWalk Holdings | 11.43M |
| Alps Group | 3.74M |
| Serina Therapeutics | 130.00K |
| iBio, Inc. | 100.00K |
| INmune Bio | 50.00K |
| eXoZymes | -700.00 |
EDSA News
- 13 days ago - Edesa Biotech 3.87M share Spot Secondary priced at $5.50 - TheFly
- 14 days ago - Edesa Biotech Announces Pricing of $25.0 Million Public Offering - GlobeNewsWire
- 14 days ago - Edesa Biotech announces offering of common stock and warrants, no amount given - TheFly
- 14 days ago - Edesa Biotech Announces Proposed Public Offering - GlobeNewsWire
- 20 days ago - Edesa Biotech Reports Fiscal 3rd Quarter 2026 Results - GlobeNewsWire
- 2 months ago - Edesa Biotech files to sell 729,241 common shares for holders - TheFly
- 2 months ago - Edesa Biotech reinstated with a Buy at Brookline - TheFly
- 2 months ago - Edesa Biotech announces $3.5M private placement - TheFly